CA125、CEA与BNP联合检测在左心衰竭早期诊断中的临床价值

doi:10.3969/j.issn.1671-7171.2026.07.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1308 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical application value of combined detection of carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and brain natriuretic peptide (BNP) for early identification of left heart failure (LHF). 【Methods】 A total of 78 patients with early LHF admitted to the hospital from January 2021 to June 2024 were enrolled as the observation group, and 85 healthy volunteers undergoing physical examination during the same period were selected as the control group. Levels of CA125, CEA, BNP and cardiac function indicators including left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV) were compared between the two groups. Pearson correlation analysis was used to analyze the correlation among above indexes. Receiver operating characteristic (ROC) curve was adopted to evaluate the diagnostic efficacy of single and combined detection of CA125, CEA and BNP in early LHF. 【Results】 The levels of CA125, CEA and BNP in the observation group were significantly higher than those in the control group (P<0.05). LVEF in the observation group was obviously lower, while LVEDV was markedly higher than that in the control group (P<0.05). Pearson correlation analysis showed CA125, CEA and BNP were negatively correlated with LVEF and positively correlated with LVEDV (P<0.05). ROC curve analysis revealed combined detection of the three indexes presented the optimal diagnostic efficiency, with an area under the curve of 0.979, a sensitivity of 96.2% and a specificity of 96.5%. 【Conclusion】 The combined detection of CA125, CEA and BNP possesses important clinical significance for early diagnosis of LHF, and it can provide reference basis for clinical early intervention.

Key words： Heart Failure CA125 Antigen Carcinoembryonic Antigen Natriuretic Peptide,Brain

Received: 25 February 2025

PACS:

R541.61

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Kaiwu
	SHI Bian
	LYU Huimei

Cite this article:

HAN Kaiwu,SHI Bian,LYU Huimei. Clinical Value of Combined Detection of CA125, CEA and BNP in Early Diagnosis of Left Heart Failure[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(7): 1061-1063.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.07.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I7/1061

[1] 吴倩,杨娟,孙斌. 血清ET-1、NT-proBNP、HIF-1α水平与急性左心衰竭患者预后的相关性[J].川北医学院学报,2024,39(8):1064-1067.
[2] 慈鸣,陈青,王英杰,等. 心力衰竭新型生物标志物的研究进展及应用[J].医学检验与临床,2024,35(4):45-49.
[3] 远洋,孟宇,韩拓,等. 酚妥拉明联合重组人脑利钠肽治疗急性左心衰竭患者的疗效及对GRP78、PTX3和GDF-15的影响[J].中国医院用药评价与分析,2023,23(1):58-61.
[4] 吴华芹,张并璇,李雨濛,等. 慢性心力衰竭病人血清CA125水平与心功能的相关性研究[J].中西医结合心脑血管病杂志,2020,18(18):2955-2958.
[5] SHI C X, VAN DER WAL H H, SILLJÉ H H W, et al. Tumour biomarkers: association with heart failure outcomes[J].J Int Med, 2020,288(2):207-218.
[6] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等. 中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志,2024,52(3):235-275.
[7] 王慧. 早期无创通气在抢救急性左心衰竭合并呼吸衰竭患者中的临床应用[J].中国实用医药,2023,18(15):37-40.
[8] 蒙艳,王雪峰,柳茵,等. NLR联合乏氧诱导因子-1α检测在老年急性左心衰竭患者中变化及临床意义[J].中国急救复苏与灾害医学杂志,2022,17(7):860-863.
[9] CASTIGLIONE V, AIMO A, VERGARO G, et al. Biomarkers for the diagnosis and management of heart failure[J].Heart Fail Rev,2022, 27(2):1-19.
[10] 中国老年医学学会心电与心功能分会,中国心衰中心联盟专家委员会,中华医学会《中华全科医师杂志》编辑委员会. 心力衰竭早期筛查与一级预防中国专家共识(2024年)[J].中华全科医师杂志,2024,23(1):7-18.
[11] 茹则古丽·图尔荪,郑颖颖. 血清CA125与心力衰竭患者的相关性分析[J].临床医学进展,2024,14(3):555-560.
[12] SAAD H, SOLIMAN H A, MAHMOUD B, et al. The pathogenic role of oxidative stress, cytokine expression, and impaired hematological indices in diabetic cardiovascular diseases[J].Inflammation,2023, 46(1):146-160.
[13] 万冬梅,赵御凯,郝学东,等. 加味真武汤联合温针治疗心肾阳虚型心动过缓的疗效及其对患者心脏自主神经功能、心功能的影响[J].实用心脑肺血管病杂志,2025,33(1):81-85.
[14] 顾杨洋,罗朋. 超声心动图联合全身免疫炎症指数对心力衰竭早期诊断的研究进展[J].临床医学进展,2024,14(11):1502-1507.